Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07514416

To Test a New Drug (LCFA-01) for Safety and PK in Healthy Adults for Bacterial Vaginosis Infection.

This study is being done to check how safe and comfortable LCFA-01 is when used inside the vagina. LCFA-01 is a natural product that contains oleic acid, and it comes as a soft gel capsule that participants will place in the vagina using their fingers.

The main purpose of the study is to make sure the product is safe and does not cause any problems or discomfort. The study will also measure how much of the product stays in the vagina and whether any of it enters the bloodstream. This helps researchers understand how the body absorbs and handles the product.

Finally, the study will also look at early signs of how the product might affect the natural bacteria in the vagina.

In the future, LCFA-01 may be used to treat bacterial vaginosis (BV).

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–40 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 1

Primary location

Allied Health Hub Morayfield

Brisbane, Queensland, 4506, Australia

Location status: Recruiting

Location contact

Dr Christopher Geoffrey Moller

CONTACT

0737374500

Dr Christopher Geoffrey Moller

PRINCIPAL_INVESTIGATOR

About this study

This study is testing a new vaginal product called LCFA-01 for the first time in humans. The goal is to see:

  • if it is safe,
  • if women can tolerate it well, and
  • what happens to the product inside the body after it's used.

Up to 30 healthy adult women who are 18 years to 40 years of age and who are not pregnant & not in menopause.

Women first go through a "Screening period" lasting up to 35 days. Doctors make sure they are healthy and can join the study.

The whole study period lasts 2 weeks:

Week 1: Using the product

Women use the vaginal product once a day for 7 days. Day 1 and Day 2: They use it at the clinic, so doctors can watch closely for safety.

Day 3 to Day 7: They use it at home.

Women also take their own vaginal swab samples every day at home. During the first week, they take the swab before using the product.

Week 2: No product

Women stop using the product but continue to self-swab at home. They come back for a check-up at the end of this week.

There will be 2 groups (cohorts), each trying a different amount of LCFA-01:

In each group, 2 out of 3 women get LCFA-01

1 out of 3 gets a placebo (a harmless, inactive product)

This helps researchers compare effects.

Only 2 women (one gets LCFA-01, one gets placebo) are treated first in each group.

Doctors watch them for 24 hours. If everything looks safe, the rest of the women in that group can begin the study.

Are there any side effects? Is the product safe and comfortable to use? Does any of the product get into the bloodstream? How long does the product stay in the vagina? How does it affect the vaginal environment?

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Females aged 18 to 40 years (inclusive) who are pre-menopausal at the time of providing informed consent
  • You should be generally healthy, with no major past illnesses, and your doctor should not see anything concerning during your check-up before starting the study.
  • Your BMI (a measure of weight and height) must be between 18.0 and 34.9.
  • You must be a non-smoker or only an occasional smoker. If you smoke 2 cigarettes or less per week (or similar, like vaping or cigars), you may still join, depending on the study doctor's decision.
  • Your blood and urine test results should be normal, unless the study doctor decides that a slightly abnormal result is not a problem.
  • You must test negative for common sexually transmitted infections (STIs) at the screening visit.
  • You must not be pregnant at Screening or when you join the study.
  • You should have regular periods, unless you are using hormonal birth control that stops your periods. If you do have regular periods, you will join the study within 5 days after your period ends.
  • You must agree not to use any vaginal products (like creams, gels, or suppositories) during the study.
  • You must agree not to have sexual intercourse during the study and also avoid:

receptive oral sex anal sex vaginal sex toys

  • If you can become pregnant, you must use a reliable form of birth control starting from Screening until 90 days after your last dose of the study product.(Using only condoms is not enough.)
  • You must be willing and able to come to all required study visits.
  • You must be willing to sign a consent form after the study has been explained to you, including how your samples may be stored for future research.

Exclusion criteria

  • Women who currently have moderate or severe vaginal symptoms (such as pain, itching, burning, or unusual discharge) at the Screening visit cannot join the study.
  • Women with physical or mental health conditions that, in the opinion of the study doctor, would make it difficult for them to follow the study rules or finish the study will not be able to participate.
  • Women who have had certain surgeries, such as:
  • removal of the uterus (full or partial hysterectomy) major surgeries on the cervix, vagina, or uterus (for example: cervical cone biopsy,removal of the cervix, or major uterine surgery)
  • cannot participate because these procedures may change the vaginal or reproductive anatomy, which could affect study results.
  • Women with certain medical conditions, including:

a. Serious diseases of the vagina, cervix, or uterus, such as:

  • cancers of the female reproductive system
  • endometriosis
  • chronic or recurrent vaginal infections

b. Uncontrolled genital herpes, meaning they had at least one active outbreak in the past 6 months.

c. Serious health problems such as: heart disease or a past heart attack chronic lung disease (like COPD) chronic kidney failure severe liver disease (cirrhosis) or any other serious condition that the study doctor believes would make it unsafe to join the study.

d. Any condition that would require using steroid medicines inside the genital area during the study. (Steroid creams used on the skin, inhalers, or nose sprays are allowed.) e. A yeast infection (vulvovaginal candidiasis) found during Screening. f. Repeated episodes of bacterial vaginosis (BV), meaning two or more episodes in the past year.

  • Women who have ever had an autoimmune disease cannot join the study.
  • Autoimmune diseases happen when the body's immune system attacks its own tissues. Examples include:

Hashimoto's thyroid disease Pernicious anemia Addison's disease Rheumatoid arthritis Lupus Multiple sclerosis Myasthenia gravis Grave's disease Celiac disease Psoriasis Sarcoidosis Scleroderma Diabetes (Type 1)

  • Also, anyone who shows signs of an autoimmune disease now, or is taking medicines that weaken the immune system, may be excluded based on the study doctor's judgment.
  • Women who were diagnosed with a cervicovaginal infection (such as gonorrhea, chlamydia, trichomonas, or Mycoplasma genitalium) within 30 days before Screening cannot join.
  • Women who had an infection requiring antibiotics or antifungal medicines within 14 days before Screening cannot join.
  • Women who used any vaginal cleaning practices in the past 14 days cannot participate.

This includes:

vaginal douching using products to clean, wash, dry, or "freshen" the vagina

  • Women who test positive for syphilis at Screening cannot join.
  • Women who have HIV cannot participate, whether the infection is treated, untreated, or well controlled.
  • Women who have chronic hepatitis B infection cannot join the study.
  • Women who are currently taking medicine to treat hepatitis C cannot participate.
  • Women who have used long-acting investigational medicines, such as injectable HIV prevention products (PrEP), within the past year cannot join.
  • Women who are using a non-hormonal IUD, like the copper T IUD, or a hormonal vaginal ring, cannot take part in the study.

Treatment and study plan

LCFA-01

Drug

LCFA-01 Drug Product is a soft gelatin capsule, containing oleic acid at 2 dosage strengths (200 mg and 400 mg).

Placebo

Drug

LCFA-01 Placebo is a soft gelatin capsule, of which the composition is similar to that of LCFA-01 Drug Product, but without the active pharmaceutical ingredient.

Primary outcomes

  1. Treatment-emergent adverse events (TEAEs)

    Time frame: Day 1 to Day 14

  2. Clinically significant changes in Physical examinations

    Time frame: Baseline, Day 2, Day 8, Day 10, Day 14

  3. Clinically significant changes in Vital Signs as per protocol

    Time frame: Baseline, Day2, Day 8, Day 10, Day 14

  4. Clinically significant changes in Safety Laboratory Parameters as per protocol

    Time frame: Baseline, Day 1, Day 2, Day 8, Day 10

  5. Self-Reported Symptoms-abnormal vaginal odor

    Time frame: Baseline to Day 14

  6. Self-Reported Symptoms-pain, tenderness

    Time frame: Baseline to Day 14

  7. Self-Reported Symptoms- dyspareunia

    Time frame: Baseline to Day 14

  8. Self-Reported Symptoms- dysmenorrhea/cramping with menses

    Time frame: Baseline to Day 14

  9. Self-Reported Symptoms- vaginal vulvar itching

    Time frame: Baseline to Day 14

  10. Self-Reported Symptoms-vulvar edema

    Time frame: Baseline to Day 14

  11. Self-Reported Symptoms- vulvar erythema

    Time frame: Baseline to Day 14

  12. Self-Reported Symptoms-vulvar lesions

    Time frame: Baseline to Day 14

  13. Self-Reported Symptoms-Bartholin or Skene's gland lesions

    Time frame: Baseline to Day 14

Secondary outcomes

  1. PK parameters derived from plasma concentration for Maximum concentration (Cmax)

    Time frame: On Day 1, 2, 8, 10

  2. Observed concentrations of LCFA-01 in vaginal samples post-dosing

    Time frame: Day 1, 2, 8, 10, 14

  3. PK parameters derived from plasma concentration for Area Under the Curve (AUC)

    Time frame: On Day 1, 2, 8, 10

  4. PK parameters derived from plasma concentration for Time to maximum concentration( Tmax)

    Time frame: On Day 1, 2, 8, 10

Study contacts

Contact information is provided by the study sponsor or research team.

Dr Caroline Mitchell, MD, MPH

CONTACT

[email protected]

+16177242182

Dr Douglas Kwon

CONTACT

[email protected]

+18572687160

Sponsors and collaborators

Lead sponsor

Massachusetts General Hospital

Other

Collaborators

  • Caroline Mitchell, MD, MPH, Massachusetts General Hospital
  • Meilin Zhu, PhD, Massachusetts General Hospital

Registry information

Official study title

A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of LCFA-01, an Intravaginal Product, in Healthy Participants for Bacterial Vaginosis Treatment

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Apr 7, 2026
Registry last updated
Jul 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.